TITLE

MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient Survival

AUTHOR(S)
Perez, Marco; Praena-Fernandez, Juan M.; Felipe-Abrio, Blanca; Lopez-Garcia, Maria A.; Lucena-Cacace, Antonio; Garcia, Angel; Lleonart, Matilde; Roncador, Guiovanna; Marin, Juan J.; Carnero, Amancio
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
MAP17 is a membrane-associated protein that is overexpressed in human tumors. Because the expression of MAP17 increases reactive oxygen species (ROS) generation through SGLT1 in cancer cells, in the present work, we investigated whether MAP17 and/or SGLT1 might be markers for the activity of treatments involving oxidative stress, such as cisplatin or radiotherapy. First, we confirmed transcriptional alterations in genes involved in the oxidative stress induced by MAP17 expression in HeLa cervical tumor cells and found that Hela cells expressing MAP17 were more sensitive to therapies that induce ROS than were parental cells. Furthermore, MAP17 increased glucose uptake through SGLT receptors. We then analyzed MAP17 and SGLT1 expression levels in cervical tumors treated with cisplatin plus radiotherapy and correlated the expression levels with patient survival. MAP17 and SGLT1 were expressed in approximately 70% and 50% of cervical tumors of different types, respectively, but they were not expressed in adenoma tumors. Furthermore, there was a significant correlation between MAP17 and SGLT1 expression levels. High levels of either MAP17 or SGLT1 correlated with improved patient survival after treatment. However, the patients with high levels of both MAP17 and SGLT1 survived through the end of this study. Therefore, the combination of high MAP17 and SGLT1 levels is a marker for good prognosis in patients with cervical tumors after cisplatin plus radiotherapy treatment. These results also suggest that the use of MAP17 and SGLT1 markers may identify patients who are likely to exhibit a better response to treatments that boost oxidative stress in other cancer types.
ACCESSION #
87624351

 

Related Articles

  • Integrative mixture of experts to combine clinical factors and gene markers. Lê Cao, Kim-Anh; Meugnier, Emmanuelle; McLachlan, Geoffrey J.; Troyanskaya, Olga // Bioinformatics;May2010, Vol. 26 Issue 9, p1192 

    Motivation: Microarrays are being increasingly used in cancer research to better characterize and classify tumors by selecting marker genes. However, as very few of these genes have been validated as predictive biomarkers so far, it is mostly conventional clinical and pathological factors that...

  • Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. Sapre, Nikhil; Selth, Luke A. // Prostate Cancer (20903111);2013, p1 

    MicroRNAs are key regulators of gene expression and play critical roles in both normal physiology and pathology. Recent research has demonstrated that these molecules are present in body fluids, such as serum, plasma, and urine, and can be readily measured using a variety of techniques. More...

  • Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. De Cecco, Loris; Berardi, Martina; Sommariva, Michele; Cataldo, Alessandra; Canevari, Silvana; Mezzanzanica, Delia; Iorio, Marilena V.; Tagliabue, Elda; Balsari, Andrea // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    We recently reported that peritumoral CpG-ODN treatment, activating TLR-9 expressing cells in tumor microenvironment, induces modulation of genes involved in DNA repair and sensitizes cancer cells to DNA-damaging cisplatin treatment. Here, we investigated whether this treatment induces...

  • A Comparative Analysis of Clinical and Molecular Factors with the Stage of Cervical Cancer in a Brazilian Cohort. Amaro-Filho, Sergio M.; Golub, Jonathan E.; Nuovo, Gerard J.; Cunha, Cynthia B.; Levi, José E.; Villa, Luisa L.; Andrade, Cecília V.; Russomano, Fabio B.; Tristão, Aparecida; Pires, Andrea; Nicol, Alcina F. // PLoS ONE;Mar2013, Vol. 8 Issue 3, p1 

    Cell cycle protein expression plays an important role in the pathophysiology of cervical cancer. However, few studies have attempted to correlate the use of these biomarkers with the clinical progression of the tumor. Objectives: 1) To analyze the expression of Ki-67, p53 and p16INK4a in...

  • LMP1 Increases Expression of NADPH Oxidase (NOX) and Its Regulatory Subunit p22 in NP69 Nasopharyngeal Cells and Makes Them Sensitive to a Treatment by a NOX Inhibitor. Sun, Jian; Hu, Chongyu; Zhu, Yinghui; Sun, Rui; Fang, Yujing; Fan, Yuhua; Xu, Fei // PLoS ONE;8/5/2015, Vol. 10 Issue 8, p1 

    Oxidative stress is thought to contribute to cancer development. Epstein–Barr virus (EBV) and its encoded oncoprotein, latent membrane protein 1 (LMP1), are closely associated with the transformation of nasopharyngeal carcinoma (NPC) and Burkitt’s lymphoma (BL). In this study, we...

  • The associations of biological parameters with the effects of radiotherapy and cisplatin-based concurrent chemoradiotherapy in uterine cervical cancer. Yueh-Chun Lee; Jiunn-Liang Ko; Tzu-Fan Wu; Chih-Hsien Wu; Yu-Fan Liu; Wea-Lung Lin; Po-Hui Wang // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 11, p21900 

    Objectives: The purpose of this study was to determine the associations of the expressions of some important biomarkers that we have previously investigated with the clinic pathological characteristics and prognoses of patients with uterine cervical cancer in Taiwan. Methods: One hundred and...

  • Targeting targeted agents: open issues for clinical trial design. Bria, Emilio; Di Maio, Massimo; Carlini, Paolo; Cuppone, Federica; Giannarelli, Diana; Cognetti, Francesco; Milella, Michele // Journal of Experimental & Clinical Cancer Research (17569966);2009, Vol. 28, p1 

    Molecularly targeted agents for the treatment of solid tumors had entered the market in the last 5 years, with a great impact upon both the scientific community and the society. Many randomized phase III trials conducted in recent years with new targeted agents, despite previous data coming from...

  • Expression of EZH2 in cervical cancer and íts relationship wíth cell proliferation and angiogenesis. LIU Ying; GAO Qing; GAO Yan-e; CHANG Li-hua; ZHANG Wei-hua; DONG Xiao-zhang; YANG Jun; LI Mu // Journal of Xi'an Jiaotong University (Medical Sciences);Sep2013, Vol. 34 Issue 5, preceding p581 

    Objective To explore the role of enhancer of zeste homolog 2 (EZH2) in the pathogenesis and development of cervical cancer, and its relationship with clinical characteristics by examining EZH2, Ki67 and CD34 expressions in normal cervix, cervical intraepithelial neoplasia (CIN) and cervical...

  • Early Detection of Breast Cancer New Biomarker Tests on the Horizon? Jotwani, Aparna C.; Gralow, Julie R. // Molecular Diagnosis & Therapy;Dec2009, Vol. 13 Issue 6, p349 

    When cancer is detected early, patients live longer, require less extensive treatment, and in general fare better than patients with more advanced disease. Breast cancer is the most commonly diagnosed cancer among women. Breast cancer screening through mammography has shown significant mortality...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics